ルベル・インターナショナル病院
| トルコ | オーストリア | スペイン | |
| 腹腔内温熱化学療法 | から $22,500 | から $40,000 | から $25,000 |
この医師は腹膜癌症に特化した腫瘍外科医であり、2019年からTeknon Oncology InstituteのCarcinomatosis Surgical Groupの一員です。彼女はワシントン病院センターでPaul Sugarbaker教授の下で専門を修了し、American Board of Surgeryの認定を受けています。<\/p>
彼女はAmerican College of SurgeonsやSociety of Surgical Oncologyなどのいくつかの著名な学会のメンバーです。彼女の学術的な役割には、Inova Fairfax Hospitalの研究ディレクターや、Virginia Commonwealth UniversityおよびGeorgetown Universityでの准教授職が含まれています。<\/p>
Dr. Joseba Rebollo Liceaga is a clinical oncologist at Quirónsalud Alicante. He focuses on personalized cancer treatments and gene-based therapies for metastatic breast cancer. Dr. Rebollo Liceaga teaches as a professor of Multidisciplinary and Personalized Oncology. He treats various conditions, including prostate, colon, and thyroid cancers.
Spanish reference centers prioritize cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy as the primary evidence-based treatment. This curative-intent approach targets peritoneal surface malignancies. Specialized multidisciplinary committees at JCI-accredited facilities manage these complex cases. Surgeons aim for complete macroscopic tumor removal during the procedure.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in Spain. Facilities like Clinica Universidad de Navarra have served 700,000 patients from 70 countries. High-volume centers often possess more experience with rare conditions like pseudomyxoma peritonei. Dr. Lana Bijelic at Centro Médico Teknon specifically trained under the pioneer of the Sugarbaker technique. This specialized expertise is essential for achieving the high cytoreduction rates reported in Spanish registries.
Patient Consensus: Patients emphasize the need for early multidisciplinary evaluation to determine if they qualify for curative-intent surgery. They note that bringing detailed pathology reports and previous imaging is vital for a clear treatment plan.
Leading Spanish hospitals like Centro Medico Teknon and Clinica Universidad de Navarra are globally recognized for carcinomatosis management. These JCI-accredited centers specialize in cytoreductive surgery and HIPEC protocols. They utilize multidisciplinary tumor boards and advanced robotic technology to treat complex abdominal malignancies for international patients.
Bookimed Expert Insight: Data shows that hospital choice in Spain depends on specific doctor affiliations rather than general reputation. While many clinics offer oncology, only a few like Hospital Vithas Valencia Turia feature leaders like Dr. Alfonso Garcia Fadrique. He authored a PhD on HIPEC quality standards. We recommend prioritizing centers with documented high volumes like Teknon. It manages 10,000 patients annually and serves as a European reference hub.
Patient Consensus: Patients emphasize that successful treatment depends more on the specific surgeon's experience with HIPEC than the hospital brand. They recommend centers in Madrid and Barcelona that provide multidisciplinary reviews of imaging and pathology before travel.
Candidates for CRS and HIPEC in Spain typically have cancers confined to the abdominal lining. Eligibility requires a low Peritoneal Cancer Index and high physical fitness. Spanish multidisciplinary boards prioritize colorectal, ovarian, and appendix cancers. Complete removal of visible tumors is necessary for success.
Bookimed Expert Insight: Spanish centers like Clinica Universidad de Navarra and Centro Médico Teknon handle massive patient volumes. This high-volume environment allows for specialized teams like the Carcinomatosis Surgical Group. Dr. Lana Bijelic at Teknon trained directly under pelvic surgery pioneers like Prof. Paul Sugarbaker. This lineage of expertise often results in more precise patient selection than general oncology centers.
Patient Consensus: Patients note that scans can underestimate disease, so a final decision often requires laparoscopy. Many emphasize that physical recovery is intense and requires significant nutritional and functional fitness beforehand.
Spanish centers report survival outcomes reaching 89% for pseudomyxoma peritonei over 3 years. Median overall survival for ovarian cancer cases is 55 months. Success depends primarily on complete cytoreductive surgery and HIPEC. Specialized facilities in Madrid and Barcelona maintain a 97% perioperative survival rate.
Bookimed Expert Insight: Spanish oncology centers like Centro Médico Teknon and Clinica Universidad de Navarra show a clear link between high patient volumes and surgical precision. Dr. Lana Bijelic at Teknon trained directly under Prof. Paul Sugarbaker, the pioneer of HIPEC. This direct lineage of expertise likely contributes to Spain's high success in achieving complete cytoreduction, which remains the single most important factor for long-term survival in carcinomatosis cases.
Patient Consensus: Patients note that outcomes vary significantly by primary tumor type. They emphasize that a second opinion from high-volume Spanish specialists often changes their eligibility for surgery.
Spanish hospitals manage language barriers through dedicated international departments and professional medical interpreters. Clinics like Clinica Universidad de Navarra provide English-speaking coordinators for oncology diagnostics. Specialized services ensure accuracy during complex carcinomatosis consultations. These teams handle pathology reviews and follow-up care to prevent errors.
Bookimed Expert Insight: While many think large facilities are best, our data shows a high concentration of expertise in Barcelona. Centro Médico Teknon serves 10,000 international patients annually with a 4.7 rating. This high volume means their staff is more accustomed to handling diverse language needs than smaller regional centers. Choosing a JCI-accredited facility like Teknon ensures standardized communication protocols are strictly followed throughout the surgical journey.
Patient Consensus: Patients note it is important to confirm English-speaking staff availability before travel. They suggest requesting written summaries of pathology and imaging to avoid misunderstandings during follow-up messages.